Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NSCLC Harboring NRG1 Fusion”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Early research (Phase 1)Active Not RecruitingNCT05919537
What this trial is testing

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Who this might be right for
Non-Small Cell Lung CancerPancreatic CancerLocally Advanced Solid Tumor+1 more
Hummingbird Bioscience 68
Testing effectiveness (Phase 2)Ended earlyNCT05588609
What this trial is testing

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Who this might be right for
NSCLC Harboring NRG1 FusionMetastatic Castration-resistant Prostate Cancer
Merus B.V. 13
Not applicableStudy completedNCT04750824
What this trial is testing

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 110
Testing effectiveness (Phase 2)Active Not RecruitingNCT02912949
What this trial is testing

Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Who this might be right for
Solid Tumours Harboring NRG1 FusionNSCLC Harboring NRG1 FusionPancreatic Cancer Harboring NRG1 Fusion+1 more
Partner Therapeutics, Inc. 250